US-based drug delivery contract development and manufacturing organization (CDMO) Particle Sciences has completed manufacturing of vaginal rings with new architecture, essentially a powdered filled tube intended for HIV prevention.
The ring, which is designed to provide the pro-drug tenofovir disoproxil fumarate for 30 days, joins several other microbicide delivery approaches under development.
The device offered complete protection in macaques against the related virus, SHIV, in studies conducted at the Center for Disease Control.
Particle Sciences CEO Mark Mitchnick said the company focuses on formulation design and manufacturing.
"Given the issues our clients face, the dosage forms we work with often require a high level of engineering and reducing complex formulations to commercially viable products is something we frequently do," Mitchnick added.
"The product itself was designed by Patrick Kiser, PhD, Associate Professor of Biomedical Engineering at Northwestern University."
The drug eluting device is funded under an NIH grant led by the Albert Einstein College of Medicine.
The company focuses on BCS II/III/IV molecules, biologics and highly potent compounds via a variety of technologies such as emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others.
